{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:35:28Z","timestamp":1777318528536,"version":"3.51.4"},"reference-count":47,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IAPorto Research Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Reported cases of anaphylaxis following COVID-19 vaccination raised concerns about the safety of these vaccines, namely in patients suffering from clonal mast cell (MC) disorders\u2014a heterogenous group of disorders in which patients may be prone to anaphylaxis caused by vaccination. This study aimed to assess the safety of COVID-19 vaccines in patients with clonal MC disorders. We performed an ambidirectional cohort study with 30 clonal MC disorder patients (n = 26 in the prospective arm and n = 4 in the retrospective arm), that were submitted to COVID-19 vaccination. Among these, 11 (37%) were males, and median age at vaccination date was 41 years (range: 5y to 76y). One patient had prior history of anaphylaxis following vaccination. Those in the prospective arm received a premedication protocol including H1- and H2-antihistamines and montelukast, while those in the retrospective arm did not premedicate. Overall, patients received a total of 81 doses, 73 under premedication and 8 without premedication. No MC activation symptoms were reported. COVID-19 vaccination seems to be safe in patients with clonal mast cell disorders, including those with prior anaphylaxis following vaccination. Robust premedication protocols may allow for vaccination in ambulatory settings.<\/jats:p>","DOI":"10.3390\/vaccines10050718","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:21:25Z","timestamp":1651652485000},"page":"718","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-617X","authenticated-orcid":false,"given":"Tiago Azenha","family":"Rama","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Servi\u00e7o de Imunologia B\u00e1sica e Cl\u00ednica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"EPIUnit\u2014Institute of Public Health, University of Porto, 4050-600 Porto, Portugal"},{"name":"Laboratory for Integrative and Translational Research in Population Health (ITR), 4050-600 Porto, Portugal"}]},{"given":"Joana","family":"Miranda","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Diana","family":"Silva","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Servi\u00e7o de Imunologia B\u00e1sica e Cl\u00ednica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"EPIUnit\u2014Institute of Public Health, University of Porto, 4050-600 Porto, Portugal"},{"name":"Laboratory for Integrative and Translational Research in Population Health (ITR), 4050-600 Porto, Portugal"}]},{"given":"Lu\u00eds","family":"Amaral","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Eunice","family":"Castro","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Alice","family":"Coimbra","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-9296","authenticated-orcid":false,"given":"Andr\u00e9","family":"Moreira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Servi\u00e7o de Imunologia B\u00e1sica e Cl\u00ednica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"EPIUnit\u2014Institute of Public Health, University of Porto, 4050-600 Porto, Portugal"},{"name":"Laboratory for Integrative and Translational Research in Population Health (ITR), 4050-600 Porto, Portugal"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Pl\u00e1cido","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa2117128","article-title":"Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina","volume":"386","author":"Lin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"ref_3","unstructured":"(2021, November 28). European Medicines Agency\u2014COVID-19 vaccines. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-vaccines."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Garvey, L.H., and Nasser, S. (2020). Allergic reactions to the first COVID-19 vaccine: Is polyethylene glycol (PEG) the culprit?. Br. J. Anaesth.","DOI":"10.1016\/j.bja.2020.12.020"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-022-00167-y","article-title":"The risk of anaphylaxis behind authorized COVID-19 vaccines: A meta-analysis","volume":"20","author":"Sobczak","year":"2022","journal-title":"Clin. Mol. Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rama, T.A., Coutinho, R.M., Mota, D., Moreira, A., and Cernada, J. (2021). Hypersensitivity to the Moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient. J. Investig Allergol Clin. Immunol., 32.","DOI":"10.18176\/jiaci.0773"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1111\/all.14794","article-title":"Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation","volume":"76","author":"Klimek","year":"2021","journal-title":"Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/all.14725","article-title":"COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: \u201cCOVID-19 vaccine anaphylaxis: PEG or not?\u201d","volume":"76","author":"Cabanillas","year":"2021","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","article-title":"Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review","volume":"9","author":"Gulen","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_16","unstructured":"Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., and Thiele, J. (2017). Mastocytosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [Revised 4th ed.]."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/pai.12647","article-title":"Evaluation of vaccination safety in children with mastocytosis","volume":"28","author":"Parente","year":"2017","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/cea.12882","article-title":"Vaccination management in children and adults with mastocytosis","volume":"47","author":"Zanoni","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4274\/jpr.galenos.2019.96720","article-title":"Occurrence of Unexpected Adverse Reactions to Vaccines in Children with Mastocytosis","volume":"7","author":"Abuhay","year":"2020","journal-title":"J. Pediatric. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/pde.14492","article-title":"Assessing vaccination reactions in pediatric patients with maculopapular cutaneous mastocytosis","volume":"38","author":"Johansen","year":"2021","journal-title":"Pediatr. Derm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2021.01.004","article-title":"mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis","volume":"147","author":"Rama","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jaip.2022.01.030","article-title":"Safety of COVID-19 vaccination in patients with clonal mast cell disorders","volume":"10","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jaip.2021.05.010","article-title":"Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome","volume":"9","author":"Kaakati","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1097\/HS9.0000000000000650","article-title":"A UK Survey Examining the Experience of Adults With Mastocytosis Receiving COVID-19 Vaccination","volume":"5","author":"Sriskandarajah","year":"2021","journal-title":"Hemasphere"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jaip.2022.01.037","article-title":"COVID-19 vaccination in the setting of mastocytosis-Pfizer-BioNTech mRNA vaccine is safe and well tolerated","volume":"10","author":"Lazarinis","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: Delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny","year":"2001","journal-title":"Leuk Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: A consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41590-022-01130-4","article-title":"Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses","volume":"23","author":"Tomalka","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1398-9995.2012.02812.x","article-title":"Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis","volume":"67","author":"Morgado","year":"2012","journal-title":"Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.jaip.2021.02.023","article-title":"COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms","volume":"9","author":"Giannetti","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/all.14958","article-title":"Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don\u2019t give up on the second dose!","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Li, D.H., Lee, E., and Song, C. (2022). Successful mRNA COVID-19 vaccination in a patient with a history of severe polyethylene glycol anaphylaxis. Res. Sq.","DOI":"10.21203\/rs.3.rs-1263943\/v1"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cabanillas, B., Novak, N., and Akdis, C.A. (2021). The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID-19 vaccines. Allergy.","DOI":"10.1111\/all.15187"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaci.2021.04.032","article-title":"Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy","volume":"148","author":"Troelnikov","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: A review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_40","first-page":"517","article-title":"Anaphylactic reactions to polyethylene glycol-containing bowel cleansing preparations after Moderna COVID-19 vaccination","volume":"54","author":"Schreiner","year":"2021","journal-title":"Endoscopy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-0716-0696-4_27","article-title":"Identification and Immunophenotypic Characterization of Normal and Pathological Mast Cells","volume":"2163","author":"Morgado","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaci.2018.10.063","article-title":"Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology","volume":"143","author":"Carter","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jaip.2021.03.041","article-title":"COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)","volume":"9","author":"Bonadonna","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Ruddy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100541","DOI":"10.1016\/j.waojou.2021.100541","article-title":"Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital","volume":"14","author":"Paoletti","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_47","first-page":"388","article-title":"Drug hypersensitivity in indolent systemic mastocytosis, without skin lesions, presenting with anaphylaxis to hymenoptera venoms","volume":"76","author":"Rama","year":"2021","journal-title":"Allergy"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/718\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:57Z","timestamp":1760137557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["vaccines10050718"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10050718","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]}}}